The enormous scale of the HIV pandemic is driving the development of new mobile phone-connected technologies, to test and track HIV in resource-limited settings.
The low cost and widespread availability of mobile phones in developing countries offers tremendous opportunities for testing in remote settings. Geographically linked information could help support better access to follow-up care and public health interventions, to prevent the spread of HIV.
Flagship 4 aims to develop nanoparticle assays to detect ultra-low levels of HIV biomarkers and transmit the results to surveillance systems. Our initial focus is on viral antigen p24, with the aim to enable detection during the first stages of disease progression and in early infant diagnosis.
